Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

Abstract Introduction Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple‐negative breast cancer (mTNBC) patients treated with eribulin mesy...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sarah S. Mougalian, Ronda Copher, Jonathan K. Kish, Lindsay McAllister, Zhixiao Wang, Mary Broscious, David Garofalo, Janna Radtchenko, Bruce A. Feinberg
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2018-09-01
Col·lecció:	Cancer Medicine
Matèries:	eribulin metastatic breast cancer real‐world survival triple negative
Accés en línia:	https://doi.org/10.1002/cam4.1705
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!